Pralsetinib
- Generic Name
- Pralsetinib
- Brand Names
- Gavreto
- Drug Type
- Small Molecule
- Chemical Formula
- C27H32FN9O2
- CAS Number
- 2097132-94-8
- Unique Ingredient Identifier
- 1WPE73O1WV
- Background
Pralsetinib, similar to the previously approved selpercatinib, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. Although multikinase inhibitors, including caboza...
- Indication
Pralsetinib is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in adult patients who are confirmed to possess a rearranged during transfection (RET) gene fusion, as determined by an FDA approved test. It is also indicated in adult and pediatric patients 12 years of age and older for the treatment of advanced or metastatic RET fus...
- Associated Conditions
- Advanced RET-fusion Non Small Cell Lung Cancer, Advanced RET-fusion thyroid cancer, Metastatic RET-fusion Non Small Cell Lung Cancer, Metastatic RET-fusion thyroid cancer
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.